By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



99 Hayden Avenue
Suite 390
Lexington  Massachusetts  02421  U.S.A.
Phone: 781-357-2333 Fax: 781-357-2399



Company News
Pulmatrix Receives Orphan Drug Designation From The FDA For Inhaled Drug To Treat Pulmonary Fungal Infections In Cystic Fibrosis Patients 8/18/2016 6:51:34 AM
Pulmatrix Reports Q2 2016 Financial Results 8/4/2016 9:55:32 AM
Pulmatrix And Mylan (MYL) Report Positive Pharmacokinetic Bioavailability Data In Pilot Study Of PUR0200 In Patients With Chronic Obstructive Pulmonary Disease (COPD) 7/19/2016 6:52:41 AM
Pulmatrix's iSPERSE Focus Of Interview With News Medical 7/6/2016 8:33:57 AM
Pulmatrix's New Life Sciences Animation Spotlights Inhaled Drug Delivery To Lungs 6/27/2016 11:40:36 AM
Pulmatrix Added To Russell Microcap Index 6/24/2016 6:30:28 AM
Pulmatrix Completes Dosing In Pilot Pharmacokinetic Evaluation Of PUR0200 In Healthy Normal Volunteers 5/25/2016 6:47:47 AM
Pulmatrix To Present At 2016 Marcum Microcap Conference 5/24/2016 8:40:31 AM
Pulmatrix Reports Q1 2016 Financial Results 5/5/2016 7:29:34 AM
Advances in Inhaled Drug Delivery Offer Major Benefits To Patients, Chief Scientific Officer For Pulmatrix Explains In Article 4/19/2016 10:33:16 AM